No Data
Guangdong Hybribio Biotech (300639.SZ): has repurchased 0.39% of its shares.
Guangdong Hybribio Biotech (300639.SZ) announced on July 31 that as of July 31, 2024, the company has cumulatively repurchased 2,505,100 shares, accounting for 0.39% of the current total share capital of the company (excluding the shares in the company's repurchase special securities account); the highest fill price for repurchase is RMB 4.81/share, and the lowest fill price is RMB 4.37/share; the total amount of funds paid is RMB 11,347,431.03 yuan (including transaction costs). This share repurchase program complies with relevant laws and regulations and the company's share repurchase plan.
Guangdong Hybribio Biotech (300639.SZ): In July, the company and its subsidiaries received a total of 3 authorized invention patents.
On July 31st, Gelonhui reported that Guangdong Hybribio Biotech (300639.SZ), along with its subsidiaries, obtained a total of three authorized invention patents in July 2024. The patents include a microfluidic chip for live cell sorting, a primer and probe combination for detecting 16 pathogenic mutations of the SLC22A5 gene, and a set of primers and reagents based on nucleic acid mass spectrometry for simultaneous detection of folate and nutrient metabolism gene SNP sites in a single tube.
Guangdong Hybribio Biotech (300639.SZ): Its subsidiary third-party medical laboratory has relevant testing technology reserves and can provide related testing services for the disease.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on July 18 that its third-party medical laboratory has the relevant testing technology reserve and can provide related testing services for the disease.
Guangdong Hybribio Biotech Obtains License for Clinical Laboratory Instruments
Guangdong Hybribio Biotech (300639.SZ): As of June 28th, the total number of shareholders in the company was 33,841.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on July 8th that as of June 28, 2024, the total number of company shareholders is 33,841.
Guangdong Hybribio Biotech (300639.SZ): Repurchased 0.10% of shares in total.
Guangdong Hybribio Biotech (300639.SZ) announced that as of June 30, 2024, the company has repurchased 655,200 shares, accounting for 0.10% of the company's current total share capital (excluding shares in the company's repurchase special securities account). The highest fill price for repurchases was RMB 4.63/share, and the lowest fill price was RMB 4.58/share. The total amount paid was RMB 3,020,811.82 (including transaction costs). This repurchase of shares complies with relevant laws, regulations, and the company's share buyback program.
No Data
